Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
Date:11/8/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 8, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2012 financial results and highlighted key clinical development activities of its two product candidates, custirsen and OGX-427.

Custirsen Clinical Development Highlights

  • The Company announced completion of patient enrollment in the primary registration Phase 3 SYNERGY study. The SYNERGY study is designed to evaluate a survival benefit for custirsen, when added to first-line chemotherapy, in men with metastatic castrate-resistant prostate cancer (mCRPC). Over 1000 men have now been enrolled.  The survival primary endpoint data are event-driven and results are expected by the end of 2013.
  • The Phase 3 AFFINITY study, evaluating a survival benefit for custirsen in combination with Jevtana® (cabazitaxel) as second-line chemotherapy in approximately 630 men with CRPC, was initiated in the third quarter. This global study will be conducted at sites throughout North America, Europe and Australia.
  • The ENSPIRIT trial, an international, randomized Phase 3 study in approximately 1,100 patients with advanced or metastatic non-small cell lung cancer (NSCLC), was initiated in the third quarter. The trial will evaluate the potential survival benefit of combining custirsen with docetaxel as a second-line chemotherapy in patients who have progressed after initial chemotherapy treatment has failed.
  • OGX-427 Clinical Development Highlights

  • Preliminary data from an investigator-sponsored Phase 2 clinical trial of OGX-427 in chemotherapy-naive patients with metastatic CRPC were presented at the European Society for Medical Oncology Annual Meeting (ESMO) in September 2012. The updated study results showed a higher number of patients without disease progression at 12 weeks and grea
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    4. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    5. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    6. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    7. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    9. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
    11. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/4/2015)... ... August 04, 2015 , ... On August 4, 2015, the White House will ... from across the United States to talk about their experiences with innovation and present ... to be among the attendees. , One of the day’s aims is to grow ...
    (Date:8/4/2015)... LOS ANGELES , Aug. 4, 2015   ... announced the recent acquisition of LifeLine Cryogenics, an east ... the New York tristate area. ... tissues, and all prepaid contracts will be honored. ... of cryogenics services, offering storage of sperm, eggs, embryos, ...
    (Date:8/4/2015)... 4, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA ... China , today announced that it will ... ended June 30, 2015, after market close on Wednesday, ... on Thursday, August 13, 2015, at 8:00 a.m. EDT ... Time) to review the Company,s financial results and provide ...
    (Date:8/3/2015)... 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... second quarter 2015 on Monday, August 10, 2015 at ... , president and chief executive officer, will lead the ... financial results for the second quarter 2015. ... section of Halozyme,s corporate website and a recording will ...
    Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2FamilyCord Announces Acquisition of LifeLine Cryogenics 2Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2
    ... - The June 30 deadline is approaching for ... $223.9 million in benefits from a class action ... attorneys lawyers involved in the court-approved settlement. ... Wisconsin's antitrust and unfair competition laws. , ,The ...
    ... - Abandoned and failed information technology programs have cost state ... trend that has some members of the Legislature wondering if ... reprogram the whole mess. , ,There's probably no need to ... government's cut-and-paste IT operations. Instead, lawmakers should look for best ...
    ... - Since it was founded in 1998, EMSystem ... of web-based communications and resource management for hospitals and emergency ... attained that stature or gotten off the ground at all ... is, in the words of one of its founders, one ...
    Cached Biology Technology:June 30 is deadline to claim up to $223.9M in Microsoft settlement 2Ethics Board site offers welcome contrast to state IT mistakes 2Ethics Board site offers welcome contrast to state IT mistakes 3Pre-eminent, web-based companies owe success to corporate venturing 2Pre-eminent, web-based companies owe success to corporate venturing 3Pre-eminent, web-based companies owe success to corporate venturing 4Pre-eminent, web-based companies owe success to corporate venturing 5Pre-eminent, web-based companies owe success to corporate venturing 6
    (Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
    (Date:7/31/2015)... Kina, 31. juli 2015 Den 10. internationale ... af BGI fra den 22. - 25. oktober i ... fejrer sin 10-års fødselsdag i år. Siden starten i ... årlige møder på ,omik,-feltet, og er en af de ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden ...
    (Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
    Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
    ... A new research study at the University of Delaware ... microorganism that lives in seawater and is related to ... and virulence. V. parahaemolyticus is a ... with the consumption of raw or undercooked seafood, particularly ...
    ... dogs in western and central Africa comes from a ... ago, probably by European colonialists. In the current issue ... of scientists from Africa, USA and France report that ... country level and that there is only limited movement ...
    ... beneficial effect of anakinra for rheumatoid arthritis patients, but ... use with other biologic medications. Rheumatoid arthritis is ... in 100 people worldwide. It affects the joints, making ... new breed of arthritis drugs licensed in the past ...
    Cached Biology News:UD research study to shed light on emerging seaborne pathogen 2UD research study to shed light on emerging seaborne pathogen 3Hope for a rabies eradication strategy in Africa 2Anakinra for rheumatoid arthritis: A modest benefit with some risk 2
    Cells are grown in triple flasks or roller bottles. Viability and growth data are generated from a parallel representative culture....
    ... Agencourt offers SNP loci identification through ... automated assay design, intensive assay validation/optimization, ... of Corriell or customer-supplied samples and ... service provides for rapid and highly ...
    ... Agencourt offers pre-validated SNP ... 1500 amplicons within 93 ... kinases, and more than ... These assays were developed ...
    ... aqueous-based mounting medium designed for the ... is especially recommended when using tracers ... It can also be used with ... (FITC), Rhodamine (TMRITC) and Texas Red. ...
    Biology Products: